Mike Grippo
Senior Vice President, Strategy & Corporate at Catalent Pharma Solutions
Meet Mike Grippo
“The cost and complexity of bringing a biologic to market can be daunting, especially when the ‘burn rate’ of small biotech companies can exceed $250,000 per week, and with 9 out of 10 drugs in clinical trials never make it to market. By providing integrated, end-to-end solutions, we help customers overcome development hurdles. It’s more important than ever that we demonstrate advantage at every stage, and save innovators the costs and delays of negotiating with multiple contractors, and the complexity and risks of handoffs and tech transfers.”